Combination therapies, effectiveness, and adherence in patients with HIV infection: Clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir

15Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

A recent addition to the anti-human immunodeficiency virus armamentarium of drugs is rilpivirine, which is a potent non-nucleoside reverse transcriptase inhibitor. This review focuses on the clinical utility of rilpivirine in terms of efficacy and virologic suppression, drug resistance, drug-drug interactions, and safety. The rilpivirine-tenofovir-emtricitabine combination is a safe and effective regimen for use in most patients who are ready to start first-line anti-human immunodeficiency virus therapy. Although drug resistance can be a problem in patients who initiate therapy on rilpivirine-based regimens with viral loads > 100,000 copies of viral RNA/mL, this problem can be alleviated by first starting therapy with efavirenz-tenofovir-emtricitabine for several months to suppress viral load to<50 copies/mL before switching to rilpivirine-based therapy. E138K is the most important mutation associated with resistance against rilpivirine and its development must be avoided whenever possible, because this mutation confers broad cross-resistance against all approved members of the non-nucleoside reverse transcriptase inhibitor family of drugs. © 2013 Wainberg.

Cite

CITATION STYLE

APA

Wainberg, M. A. (2013, February 5). Combination therapies, effectiveness, and adherence in patients with HIV infection: Clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. HIV/AIDS - Research and Palliative Care. https://doi.org/10.2147/HIV.S32377

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free